Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
3BDO
Cat. No.:
OB0225LY-0416
Appearance:
Solid
Purity:
≥96%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
3BDO is a small molecule compound with the potential to influence metabolic pathways.
Synonym:
890405-51-3; 3-Benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one; 3-Benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one; 3-Benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one; 3-BDO
CAS No.:
890405-51-3
Compound CID:
16216349
Formula:
C18H17NO5
Formula Weight:
327.33
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
3BDO can be used for metabolic studies or play an important role in drug screening.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
mTOR
Pathways:
Autophagy; PI3K/Akt/mTOR signaling; Apoptosis
Plate Number:
AOCL-6
Plate Location:
d2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
150 mg/mL; 458.25 mM
Ethanol Max Solubility:
20 mg/mL; 61.10 mM
ALogP:
3.782
HBA_Count:
3
HBD_Count:
0
Rotatable Bond:
6
